Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the...

Full description

Saved in:
Bibliographic Details
Main Authors Mccartney, Jason, Cleveland, Thomas, Uy, Johnny, Mcauley-Aoki, Rachel, Termin, Andreas P, Abela, Alexander Russell, Krenitsky, Paul John, Alcacio, Timothy, Zhang, Beili, Pierre, Fabrice Jean Denis, Khatuya, Haripada, Hughes, Robert M, Hadida Ruah, Sara Sabina, Frieman, Bryan A, Busch, Brett Bradley, Siesel, David Andrew, Baek, Minson, Joshi, Pramod Virupax, Paraselli, Prasuna, Van Goor, Fredrick, Zhou, Jinglan, Miller, Mark Thomas, Melillo, Vito, Anderson, Corey, Grootenhuis, Peter, Keshavarz-Shokri, Ali
Format Patent
LanguageEnglish
Published 28.04.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
Bibliography:Application Number: NZ20170752486